Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by Pimpovishon Dec 29, 2020 6:14pm
191 Views
Post# 32193996

RE:RE:RE:RE:64.5 million traded at 3.5 cents average

RE:RE:RE:RE:64.5 million traded at 3.5 cents averageI'm here for the value play so I'll hold and see where this goes. There's no guesswork when you're looking at the potential. The guesswork is determining where to optimize an exit. Post rollback there will be approx 55,500,000 shares taking into account the $2.75 million PP. At 70 cents, this gives the company a pegged value of $39 million Cdn. This is wherein lies the massive opportunity for ROI. We have already demonstrated comparable peers trade anywhere from $250 million US to $1 billion US. The glaring value disconnect is what has brought many new investors into the stock. There's a 10x potential ROI that's readily discernible if you do some minimal homework. A whale brought me here and I know 3 other connnected whales have recently bought in. I personally like the consolidation. This will position the company for greater upside from an institutional perspective. A tighter float and a heavily discounted valuation is attractive to more particular investors. Further, it will attract analyst coverage and they will be able to competently attribute a more normalized valuation based on peer reality.  For all these reasons, this is a hold for me as I want to maximize the ROI opportunity and not trade out for a lesser return. This is my assessment only. Other investors will have to make their own determination.
<< Previous
Bullboard Posts
Next >>